scholarly journals Metabolic plasticity allows cancer cells to thrive under nutrient starvation

2021 ◽  
Vol 118 (14) ◽  
pp. e2102057118
Author(s):  
Wilhelm Palm
2006 ◽  
Vol 66 (3) ◽  
pp. 1751-1757 ◽  
Author(s):  
Suresh Awale ◽  
Jie Lu ◽  
Surya K. Kalauni ◽  
Yukiko Kurashima ◽  
Yasuhiro Tezuka ◽  
...  

2018 ◽  
Vol 1859 ◽  
pp. e104
Author(s):  
Ljudmila Ounpuu ◽  
Aleksandr Klepinin ◽  
Elen Niemeister ◽  
Heiki Vija ◽  
Tuuli Kaambre

2020 ◽  
Vol 74 (2) ◽  
pp. 495-500 ◽  
Author(s):  
Rui Tang ◽  
Atsushi Kimishima ◽  
Andi Setiawan ◽  
Masayoshi Arai

Science ◽  
2019 ◽  
Vol 366 (6468) ◽  
pp. 1013-1021 ◽  
Author(s):  
Robert D. Leone ◽  
Liang Zhao ◽  
Judson M. Englert ◽  
Im-Meng Sun ◽  
Min-Hee Oh ◽  
...  

The metabolic characteristics of tumors present considerable hurdles to immune cell function and cancer immunotherapy. Using a glutamine antagonist, we metabolically dismantled the immunosuppressive microenvironment of tumors. We demonstrate that glutamine blockade in tumor-bearing mice suppresses oxidative and glycolytic metabolism of cancer cells, leading to decreased hypoxia, acidosis, and nutrient depletion. By contrast, effector T cells responded to glutamine antagonism by markedly up-regulating oxidative metabolism and adopting a long-lived, highly activated phenotype. These divergent changes in cellular metabolism and programming form the basis for potent antitumor responses. Glutamine antagonism therefore exposes a previously undefined difference in metabolic plasticity between cancer cells and effector T cells that can be exploited as a “metabolic checkpoint” for tumor immunotherapy.


2006 ◽  
Vol 16 (3) ◽  
pp. 581-583 ◽  
Author(s):  
Suresh Awale ◽  
Eduardo M.N. Nakashima ◽  
Surya K. Kalauni ◽  
Yasuhiro Tezuka ◽  
Yukiko Kurashima ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Yijia Li ◽  
Yangzhe Wu ◽  
Yi Hu

Cellular metabolism of both cancer and immune cells in the acidic, hypoxic, and nutrient-depleted tumor microenvironment (TME) has attracted increasing attention in recent years. Accumulating evidence has shown that cancer cells in TME could outcompete immune cells for nutrients and at the same time, producing inhibitory products that suppress immune effector cell functions. Recent progress revealed that metabolites in the TME could dysregulate gene expression patterns in the differentiation, proliferation, and activation of immune effector cells by interfering with the epigenetic programs and signal transduction networks. Nevertheless, encouraging studies indicated that metabolic plasticity and heterogeneity between cancer and immune effector cells could provide us the opportunity to discover and target the metabolic vulnerabilities of cancer cells while potentiating the anti-tumor functions of immune effector cells. In this review, we will discuss the metabolic impacts on the immune effector cells in TME and explore the therapeutic opportunities for metabolically enhanced immunotherapy.


2018 ◽  
Author(s):  
Dongya Jia ◽  
Mingyang Lu ◽  
Kwang Hwa Jung ◽  
Jun Hyoung Park ◽  
Linglin Yu ◽  
...  

AbstractMetabolic plasticity enables cancer cells to switch their metabolism phenotypes between glycolysis and oxidative phosphorylation (OXPHOS) during tumorigenesis and metastasis. However, it is still largely unknown how cancer cells orchestrate gene regulation to balance their glycolysis and OXPHOS activities for better survival. Here, we establish a theoretical framework to model the coupling of gene regulation and metabolic pathways in cancer. Our modeling results demonstrate a direct association between the activities of AMPK and HIF-1, master regulators of OXPHOS and glycolysis respectively, with the activities of three metabolic pathways: glucose oxidation, glycolysis and fatty acid oxidation (FAO). Guided by the model, we develop metabolic pathway signatures to quantify the activities of glycolysis, FAO and the citric acid cycle of tumor samples by evaluating the expression levels of enzymes involved in corresponding processes. The association of AMPK/HIF-1 activity with metabolic pathway activity, predicted by the model and verified by analyzing the gene expression and metabolite abundance data of patient samples, is further validated by in vitro studies of aggressive triple negative breast cancer cell lines.


Sign in / Sign up

Export Citation Format

Share Document